GlaxoSmithKline PLC Valuation
| GSK Stock | USD 39.24 0.17 0.43% |
At this time, the firm appears to be undervalued. GlaxoSmithKline PLC ADR retains a regular Real Value of $44.77 per share. The prevalent price of the firm is $39.24. Our model calculates the value of GlaxoSmithKline PLC ADR from evaluating the firm fundamentals such as return on asset of 0.0653, and Return On Equity of 0.23 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting GlaxoSmithKline PLC's valuation include:
Price Book 4.4892 | Enterprise Value | Enterprise Value Ebitda 11.1986 | Price Sales 2.5493 | Forward PE 8.8028 |
Undervalued
Today
Please note that GlaxoSmithKline PLC's price fluctuation is very steady at this time. Calculation of the real value of GlaxoSmithKline PLC ADR is based on 3 months time horizon. Increasing GlaxoSmithKline PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
GlaxoSmithKline PLC's intrinsic value may or may not be the same as its current market price of 39.24, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 39.24 | Real 44.77 | Target 45.07 | Hype 39.34 | Naive 38.89 |
The intrinsic value of GlaxoSmithKline PLC's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence GlaxoSmithKline PLC's stock price.
Estimating the potential upside or downside of GlaxoSmithKline PLC ADR helps investors to forecast how GlaxoSmithKline stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GlaxoSmithKline PLC more accurately as focusing exclusively on GlaxoSmithKline PLC's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use GlaxoSmithKline PLC's intrinsic value based on its ongoing forecasts of GlaxoSmithKline PLC's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against GlaxoSmithKline PLC's closest peers.
GlaxoSmithKline PLC Cash |
|
GlaxoSmithKline Valuation Trend
Knowing GlaxoSmithKline PLC's actual value is paramount for traders when making sound investment determinations. Using both GlaxoSmithKline PLC's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
GlaxoSmithKline PLC Total Value Analysis
GlaxoSmithKline PLC ADR is currently projected to have company total value of 96.82 B with market capitalization of 79.99 B, debt of 16.99 B, and cash on hands of 3.72 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the GlaxoSmithKline PLC fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
96.82 B | 79.99 B | 16.99 B | 3.72 B |
GlaxoSmithKline PLC Investor Information
About 17.0% of the company shares are owned by institutional investors. The book value of GlaxoSmithKline PLC was currently reported as 3.35. The company has Price/Earnings To Growth (PEG) ratio of 0.84. GlaxoSmithKline PLC ADR last dividend was issued on the 21st of February 2025. The entity had 1226:1000 split on the 22nd of July 2022. Based on the measurements of operating efficiency obtained from GlaxoSmithKline PLC's historical financial statements, GlaxoSmithKline PLC ADR may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.12 | 0.1282 |
|
| |||||
| Total Cash From Operating Activities | 5 B | 6.6 B |
|
| |||||
| Operating Income | 5 B | 4 B |
|
|
GlaxoSmithKline PLC Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. GlaxoSmithKline PLC has an asset utilization ratio of 52.77 percent. This suggests that the Company is making $0.53 for each dollar of assets. An increasing asset utilization means that GlaxoSmithKline PLC ADR is more efficient with each dollar of assets it utilizes for everyday operations.GlaxoSmithKline PLC Ownership Allocation
GlaxoSmithKline PLC ADR has a total of 2.03 Billion outstanding shares. Roughly 82.88 (percent) of GlaxoSmithKline PLC outstanding shares are held by general public with 0.059 % owned by insiders and only 17.06 pct. by outside corporations. Please note that on November 28, 2024, Representative Marjorie Taylor Greene of US Congress acquired under $15k worth of GlaxoSmithKline PLC ADR's common stock.GlaxoSmithKline PLC Profitability Analysis
The company reported the last year's revenue of 31.38 B. Total Income to common stockholders was 2.95 B with profit before taxes, overhead, and interest of 22.53 B.GlaxoSmithKline PLC Past Distributions to stockholders
About GlaxoSmithKline PLC Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of GlaxoSmithKline PLC ADR. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of GlaxoSmithKline PLC ADR based exclusively on its fundamental and basic technical indicators. By analyzing GlaxoSmithKline PLC's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of GlaxoSmithKline PLC's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of GlaxoSmithKline PLC. We calculate exposure to GlaxoSmithKline PLC's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GlaxoSmithKline PLC's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 22.3 B | 14.9 B | |
| Pretax Profit Margin | 0.11 | 0.11 | |
| Operating Profit Margin | 0.13 | 0.12 | |
| Net Profit Margin | 0.08 | 0.08 | |
| Gross Profit Margin | 0.71 | 0.79 |
A single share of GlaxoSmithKline PLC represents a small ownership stake in the entity. As a stockholder of GlaxoSmithKline, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
GlaxoSmithKline PLC Dividends Analysis For Valuation
At this time, GlaxoSmithKline PLC's Dividends Paid is quite stable compared to the past year. Dividend Yield is expected to rise to 0.04 this year, although the value of Dividend Payout Ratio will most likely fall to 0.82. . At this time, GlaxoSmithKline PLC's Retained Earnings are quite stable compared to the past year. Price Earnings Ratio is expected to rise to 27.57 this year, although the value of Earnings Yield will most likely fall to 0.04.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 2.4 B | 3.4 B | |
| Dividend Yield | 0.04 | 0.04 | |
| Dividend Payout Ratio | 0.95 | 0.82 | |
| Dividend Paid And Capex Coverage Ratio | 1.21 | 1.44 |
There are various types of dividends GlaxoSmithKline PLC can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of GlaxoSmithKline shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from GlaxoSmithKline PLC ADR directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When GlaxoSmithKline pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of GlaxoSmithKline PLC by the value of the dividends paid out.
GlaxoSmithKline PLC Growth Indicators
Investing in growth stocks can be very risky. If the company such as GlaxoSmithKline PLC does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 4.1 B | |
| Quarterly Earnings Growth Y O Y | 0.173 | |
| Forward Price Earnings | 8.8028 |
GlaxoSmithKline PLC Current Valuation Indicators
GlaxoSmithKline PLC's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final GlaxoSmithKline PLC's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as GlaxoSmithKline PLC, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use GlaxoSmithKline PLC's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes GlaxoSmithKline PLC's worth.When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.173 | Dividend Share 0.61 | Earnings Share 1.62 | Revenue Per Share | Quarterly Revenue Growth 0.008 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.